ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
0.00%
US Tech 100
19,208.80
1.05%
Dow Jones
40,287.53
0.00%
Brent Oil
81.275
-1.22%
Bitcoin
67,675.43
-0.71%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Cartesian Therapeutics Inc (RNAC) Quote

Cartesian Therapeutics Inc

Cartesian Therapeutics Inc (RNAC)

NASDAQ
16.16
-0.53
(-3.18%)
Closed July 19 4:00PM
Delayed by 15 minutes
16.16
0.00
( 0.00% )
Pre Market: 4:29AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
16.16
Bid
16.00
Ask
18.58
Volume
11
0.00 Day's Range 0.00
11.665 52 Week Range 42.60
Market Cap
287.584M
Previous Close
16.16
Open
-
Last Trade
1
@
16.4
Last Trade Time
08:38:48
Financial Volume
-
VWAP
-
Average Volume (3m)
156,430
Shares Outstanding
17,796,053
Dividend Yield
-
PE Ratio
-1.31
Earnings Per Share (EPS)
-12.35
Revenue
26M
Net Profit
-219.71M

About Cartesian Therapeutics Inc

Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL... Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.selectabio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Cartesian Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RNAC. The last closing price for Cartesian Therapeutics was $16.16. Over the last year, Cartesian Therapeutics shares have traded in a share price range of $ 11.665 to $ 42.60.

Cartesian Therapeutics currently has 17,796,053 shares outstanding. The market capitalization of Cartesian Therapeutics is $287.58 million. Cartesian Therapeutics has a price to earnings ratio (PE ratio) of -1.31.

RNAC Latest News

More News

Cartesian Therapeutics Announces New Employment Inducement Grants

GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...

July 08 2024
GlobeNewswire Inc.

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for...

July 02 2024
GlobeNewswire Inc.

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for...

July 02 2024
GlobeNewswire Inc.

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at...

July 02 2024
GlobeNewswire Inc.

Cartesian Therapeutics Announces New Employment Inducement Grant

GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...

June 06 2024
GlobeNewswire Inc.

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for...

May 22 2024
GlobeNewswire Inc.

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...

May 13 2024
GlobeNewswire Inc.

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024 On track to dose first patient in Phase...

May 08 2024
GlobeNewswire Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the...

May 06 2024
Business Wire

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported...

April 22 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.22-7.0195627157717.3820.9916.0614111417.34339286CS
4-6.2-27.728085867622.3629.6515.3128313718.5276582CS
12-5.58-25.666973321121.7441.8715.3115643021.86346848CS
26-7.873-32.759122872724.03341.8711.66535824820.13368523CS
52-8.035-33.209340772924.19542.611.66554426523.27148924CS
156-8.035-33.209340772924.19542.611.66554426523.27148924CS
260-8.035-33.209340772924.19542.611.66554426523.27148924CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 1.2701
(84.39%)
18.97M
NCPLNetcapital Inc
$ 0.1418
(36.35%)
36.24M
SERVServe Robotics Inc
$ 10.25
(35.76%)
25.92M
RRRichtech Robotics Inc
$ 1.83
(24.49%)
13.97M
NUKKNukkleus Inc
$ 0.3964
(23.88%)
1.89M
HUBCWHub Cyber Security Ltd
$ 0.0121
(-47.39%)
1.67k
XCURExicure Inc
$ 0.40
(-25.25%)
494.41k
SNTGSentage Holdings Inc
$ 2.03
(-18.15%)
27.59k
PIRSPieris Pharmaceuticals Inc
$ 6.00
(-17.24%)
11
BCBPBCB Bancorp Inc
$ 10.20
(-16.53%)
629
NCPLNetcapital Inc
$ 0.1418
(36.35%)
36.24M
SERVServe Robotics Inc
$ 10.25
(35.76%)
25.92M
MIRAMIRA Pharmaceuticals Inc
$ 1.2701
(84.39%)
18.97M
RRRichtech Robotics Inc
$ 1.83
(24.49%)
13.97M
MAXNMaxeon Solar Technologies Ltd
$ 0.2272
(5.38%)
10.31M

Discussion

View Full Feed
Gmenfan Gmenfan 1 minute ago
Mornin' POSSH. That's great!!!
dexprs dexprs 1 minute ago
iShares Trust Russell 2000 Index Fund: Pivot points
THE FLY 8:22 AM ET 7/22/2024
The following are the pivot points for the iShares Trust Russell 2000 Index Fund. Pivot High: $217.75, Pivot Low: $214.95. These were calculated using the DeMark method. It is generally believed to be bul
work-n-hard work-n-hard 1 minute ago
Have read "she's" entire affidavit and IMO, I commend you in taking your profit, while it was still there.
Many allegations that shareholders are not aware of, again, IN MY OWN OPINION.
YCRM
palaypu0406 palaypu0406 1 minute ago
I have advised what I should ...and its purely your internal decision what to do...
ITUP
trucker20 trucker20 2 minutes ago
I read your posts once in a while for amusement, although I have you on ignore. You were saying the same thing when the stock went as low as .03, 04 ,05 ...... Why do you keep banging the same drum? Time to change your drum. In fact, time to buy and make some money.
BBUZ
nicehit nicehit 2 minutes ago
Who are these Affiliates of NSAV? Were they employees of NSAV or Contractors of NSAV? Did an NSAV official sign the contract? Did they breach the so-called contract for non-payment?

Lot of questions
NSAV
barnstormer barnstormer 2 minutes ago
That would be great, if it happens, but I've learned to tamp down my expectations with this company, anticipating approval the Sept to Oct timeframe hopefully.
NWBO
TrendTrade2016 TrendTrade2016 2 minutes ago
DILUTE THEN SPLIT
NCPL
jimmybob jimmybob 3 minutes ago
JB rant if you missed -> https://www.optionmillionaires.com/jb-pre-market-rant-july-22nd-2024/
LVerstee LVerstee 3 minutes ago
My weathmanager takes care of everything. I pay him. Since I have time on my hands I look at which of my investments is underperforming and why.
ITUP
Viewmont Viewmont 3 minutes ago
Deep Blue
@DeepBlueEquity
$HIRU
A free trade deal with the United Arab Emirates will include the gulf state tapping its sovereign wealth fund to invest in the extraction and processing of Australian critical minerals.
https://x.com/DeepBlueEquity/status/1815372497400791
HIRU
Gmenfan Gmenfan 4 minutes ago
https://i0.wp.com/politicallyincorrecthumor.com/wp-content/uploads/2024/07/message-fbi-mistakes-favor-party-power-not-mistakes.jpg?resize=533%2C384&ssl=1
splintered sunlight splintered sunlight 4 minutes ago
Let's hope so!!!!!!
PGAS
Gmenfan Gmenfan 4 minutes ago
https://i0.wp.com/politicallyincorrecthumor.com/wp-content/uploads/2024/07/message-fbi-mistakes-favor-party-power-not-mistakes.jpg?resize=533%2C384&ssl=1
TrendTrade2016 TrendTrade2016 4 minutes ago
REVERSE SPLIT MEETING WEDSDAY..CATCH A FEW SHEEP OUT IN THE PASTURE
NCPL
urge2surge urge2surge 5 minutes ago
7/10....We anticipate to become current within next two months. We see this as a one off in preparation for a potential uplist to a bigger exchange as a larger firm than we have been historically been. The numbers will speak for themselves.

Hope all is clear. Thank you for your patie
FDCT
jedijazz jedijazz 5 minutes ago
$OCTO - A run back to all time highs? "Investors Bullish After Eightco Holdings Reports YoY Revenue Surge To $75.3 Million, 137% Higher Than 2022" https://www.barchart.com/story/news/25568545/investors-bullish-after-eightco-holdings-reports-yoy-revenue-surge-to-753-million-137-higher-than-2022
OCTO
jedijazz jedijazz 5 minutes ago
$OCTO - A run back to all time highs? "Investors Bullish After Eightco Holdings Reports YoY Revenue Surge To $75.3 Million, 137% Higher Than 2022" https://www.barchart.com/story/news/25568545/investors-bullish-after-eightco-holdings-reports-yoy-revenue-surge-to-753-million-137-higher-than-2022
OCTO
TJG TJG 5 minutes ago
I agree, I am at a total loss as to why they can not find anything to share that would not be a violation of the NDA's they have signed with Contrivian and the 3 LOI company's. A complete black out for the past 7 months is just ridiculous. We do have new people on board, COO and CFO but thats not
AFFU

Your Recent History

NASDAQ
RNAC
Cartesian Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved